profit from every $100 of sales.
$0$100
Cyclerion Therapeutics
We have no price for Cyclerion Therapeutics since 14 October 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$3.36-85.71% today
-63.5% in 1 year
1-year low $3.361-year high $45.92
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Cyclerion Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $297,000 in 2022 to $2.07 million in 2025, with -$3.53 million of profit last year.
SalesProfit
Cyclerion Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cyclerion Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cyclerion Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 2 | 2 | |
| – | – | – | – | |
| -19 | -10 | -4 | -5 | |
| -18 | -10 | -4 | -5 | |
| -44 | -5 | -3 | -4 | |
| -20.28 | -2.25 | -1.21 | -1.11 | |
| – | – | – | – | |
| -6,242.4% | – | -181.4% | -239.8% | |
| -14,841.1% | – | -152.9% | -170.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 18 | 13 | 10 | 10 |
| Cash | 13 | 8 | 3 | 3 |
| Total debt | – | – | – | – |
| Total liabilities | 8 | 2 | 1 | 1 |
| 10 | 11 | 9 | 9 | |
| 2 | 2 | 3 | 3 | |
| -140.1% | -67.5% | -32.4% | -43.2% | |
| -421.7% | -46.6% | -34.5% | -38.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -41 | -21 | -4 | -3 | |
| – | – | – | – | |
| -41 | -21 | -4 | -3 | |
| Dividends paid | – | – | – | – |
| – | – | 0 | 0 | |
| 6 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- 2.0×
- 1.1×
- –
- –
- -147.5%
- -157.0%
- 0.0%
Profitability
- 100.0%
- -239.8%
- -170.1%
- -335.9%
- -99.0%
- -129.8%
- -62.1%
- -62.0%
- -99.0%
- 82.9%
Growth
- +91.1%
- –
- +23.5%
- –
- +13.3%
Financial health
- -0.7×
- 0.00
- 0.0%
- –
- 1.80
- 1.80
- 0.23
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 964
Top 5%of 911
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.76 | -17.20 | +95.6% |
| Mar 30, 2026 | -0.19 | -0.38 | +50.0% |
| Mar 25, 2026 | -0.38 | -0.38 | +0.0% |
| Nov 12, 2025 | -0.30 | – | – |
| Aug 5, 2025 | -0.11 | – | – |
| May 6, 2025 | -0.56 | – | – |
| Mar 4, 2025 | 0.22 | – | – |
| Nov 14, 2024 | -0.29 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
49No pass
Philip Fisher
52No pass
Peter Lynch
73Pass
Joel Greenblatt
2No pass
Charlie Munger
40No pass
Terry Smith
45No pass
Questions about Cyclerion Therapeutics
Is Cyclerion Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cyclerion Therapeutics AI analysis
What does Cyclerion Therapeutics do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. It is in Biotechnology.
Does Cyclerion Therapeutics pay a dividend?
No. Cyclerion Therapeutics does not pay a dividend at the moment; in 2025 it returned $130,000 to shareholders by buying back its own shares.
Is Cyclerion Therapeutics stock halal?
No. Cyclerion Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 144% of its market value, at or above the 33% limit. How we check
How has Cyclerion Therapeutics stock done over the past year?
Down 63.5% over the past twelve months, to $3.36. It traded between $3.36 and $45.92 and is 92.7% below its high.
Who are Cyclerion Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cyclerion Therapeutics's.
Prices: daily closes to Oct 14, 2026. Fundamentals: company reports via invest-like data.